ArticleFrontiers in microbiology2026
Integrating isothermal amplification with magnetic flocculation and DNA-guided PfAgo for SARS-CoV-2 detection.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The recurrent threat of respiratory infectious disease outbreaks creates an urgent need for diagnostic tests that are rapid, portable, and user-friendly, applicable across diverse settings-from central laboratories and hospitals to field deployments, resource-limited regions, and home use. Methods: In response, we developed three novel nucleic acid detection platforms-RT-RAA-MPs, RT-RAA-F-PfAgo, and RT-RAA-L-PfAgo-that integrate reverse transcription-recombinase-aided amplification (RT-RAA) with distinct instrument-free readout mechanisms. These systems utilize custom-designed primers and guide DNA (gDNA) targeting the SARS-CoV-2 N and ORF genes. Results: Performance evaluation demonstrated high analytical sensitivity, with detection limits of 10 Discussion: With lyophilized reagent compatibility and minimal equipment requirements, these platforms are readily adaptable for a wide range of applications, including clinical diagnosis at all hospital levels, point-of-care screening, border control inspection, and environmental monitoring. This work establishes a versatile, reliable, and deployable toolkit for effective outbreak response and decentralized molecular diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.